AstraZeneca’s Tozorakimab Has Already Won the COPD Biologic Race — The Market Just Doesn’t Know It Yet

Pull up AstraZeneca’s Phase III press release from the OBERON and TITANIA trials and read past the topline. Tozorakimab didn’t just reduce COPD exacerbations — it did so by hitting a target that the rest of the respiratory biologic field has structurally avoided: oxidized IL-33, the damage-signal isoform that activates airway epithelial remodeling through a pathway entirely separate from the canonical ST2 receptor. Every other anti-IL-33 program in development has aimed at the same canonical signal. AstraZeneca aimed at two.

The street’s read is predictable: another biologic hits Phase III in a respiratory indication, respiratory is hot, file it and price it. But that comparison conceals what’s structurally different here, and what’s structurally different has direct implications for peak sales, payer negotiations, and the competitive durability of the franchise through the next decade.

The Mechanism the Competition Cannot Copy

Here is the problem with every other anti-IL-33 or anti-ST2 antibody in development: they block the reduced form of IL-33, the cytokine in its native signaling state. That covers eosinophilic inflammation, the T2-driven pathway that made dupilumab a blockbuster in asthma. In COPD, particularly in patients who smoke or have sustained oxidative stress, IL-33 doesn’t stay in its reduced form. Oxidized IL-33 activates a structurally distinct receptor complex — RAGE and EGFR on the airway epithelium — that drives mucus hypersecretion, impairs wound closure, and accelerates epithelial remodeling. Blocking ST2 alone leaves this entire arm of the disease biology running unopposed.

Tozorakimab blocks both. Its dual mechanism inhibits IL-33 signaling through the ST2 receptor for the reduced isoform and through the RAGE/EGFR complex for the oxidized isoform — the only antibody in clinical development to do both. That’s not a differentiation talking point for a medical affairs deck. That’s a structural moat against follow-on programs that would need to redesign their binding epitopes from scratch to compete on the same mechanistic ground.

The commercial implication is sharper than most analysts have priced in. COPD is heterogeneous in ways that asthma never fully was — exacerbation-prone patients, emphysema-predominant patients, patients with chronic bronchitis characterized by the exact mucus hypersecretion that IL-33ox drives. If tozorakimab’s OBERON and TITANIA data can be stratified to show differential benefit in that chronic bronchitis subpopulation, AstraZeneca has the architecture for a label that carves out market share from small-molecule LAMA/LABA combinations, not just competing biologics. That’s a fundamentally different commercial addressable market.

What a $1.68 Billion Ceiling Actually Means

The global COPD biologics market reached $604.70 million in 2024 and is projected to hit $1.68 billion by 2033, growing at a 12.1% CAGR. Read that number carefully, because it is simultaneously an opportunity and a warning.

$1.68 billion total market by 2033 is not a blockbuster ceiling for a single product — it’s a ceiling for an entire category, and that category’s first approved biologic in COPD, dupilumab (cleared in 2024), has not yet become an entrenched standard of care to anchor pricing expectations. Dupilumab in asthma generates that figure in a single quarter. The COPD biologic market is pre-formation, which means the sponsor who establishes the first durable efficacy signal doesn’t just capture share — they build the reimbursement infrastructure that every subsequent entrant has to navigate.

That’s where the FDA’s Fast Track Designations matter more than the market gives them credit for. Tozorakimab received Fast Track Designation for COPD in December 2024, following an earlier designation for severe viral lower respiratory tract disease in November 2023. Two Fast Track Designations across two indications tells you something about how the FDA is reading this target’s platform potential. It also accelerates the rolling review process in a way that meaningfully compresses the time-to-approval window for a program that has now demonstrated Phase III efficacy in replicate trials.

First approval in a nascent biologic category writes the payer playbook. AstraZeneca’s commercial team will effectively negotiate tozorakimab’s reimbursement criteria before a single competitor has an approved comparator to anchor the conversation. That’s not a small advantage. That’s the difference between a product that achieves formulary access in year one and one that spends three years in coverage reviews.

The Board Decision Hidden Inside the Biology

For biotech CEOs and BD leads watching this space, tozorakimab’s OBERON/TITANIA readout carries a strategic signal that goes beyond the specific asset. AstraZeneca chose to invest in a dual-mechanism antibody when the simpler path — blocking IL-33 at ST2 alone, following the asthma playbook — was available. That bet required understanding that COPD pathophysiology diverges from asthma in the oxidative stress environment of chronically damaged lungs, and designing the molecule accordingly rather than repurposing the same binding strategy that worked upstream.

The competitive read for everyone else in the anti-IL-33 space is uncomfortable. Any program targeting ST2 alone now faces a two-part problem: demonstrating meaningful COPD efficacy without the IL-33ox arm covered, and doing so against a competitor that will have filed a BLA in the indication before most rivals complete Phase II enrollment. That’s not a gap that can be bridged with faster execution — it requires a different molecule.

Mid-cap respiratory companies without a differentiated IL-33 program should be running scenario analyses right now on what a tozorakimab approval does to their pipeline valuations. The risk-adjusted NPV of a me-too ST2 antibody in COPD just deteriorated materially. The smarter BD move, for anyone holding such an asset, may be to pivot the program toward asthma — where Phase II data from tozorakimab’s ongoing Phase II asthma investigation hasn’t yet established the same kind of head start — rather than chase a Phase III winner in COPD with a mechanistically inferior asset.

For investors, the question to model is not whether tozorakimab gets approved — two positive replicate Phase III trials in a Fast Track program is about as clean a regulatory runway as respiratory medicine offers. The real modeling exercise is what tozorakimab does to the COPD biologics market size itself. A credible, differentiated biologic with a mechanism that addresses both inflammatory and structural disease components could pull patients who have historically been managed on maximally titrated bronchodilators into the biologic category for the first time. That’s market creation, not just market capture — and market creation is what turns a $1.68 billion forecast into a rounding error on the actual peak sales number.

AstraZeneca built a molecule for the disease that COPD actually is, not the disease the asthma playbook assumed it would be. The question every BD team in respiratory needs to answer before year-end is whether their pipeline was designed the same way — or whether they’ve been optimizing for a patient population that tozorakimab’s label will define out of the addressable market entirely.

References

1. Nature Biotechnology — “Newcomer anti-IL-33 makes strides in COPD”
2. PubMed / NCBI — “Oxidized IL-33 drives COPD epithelial pathogenesis via RAGE/EGFR pathway”
3. AstraZeneca — “Tozorakimab met primary endpoint in OBERON and TITANIA Phase III trials in patients with COPD”
4. DataM Intelligence — “COPD Biologics Market Growth & Forecast (2025–2033)”
5. Respiratory Therapy — “Tozorakimab: Dual Mechanism and Reduced COPD Exacerbations”
6. Patient Worthy — “AstraZeneca’s Tozorakimab Shows Promise as First-in-Class COPD Breakthrough”